TABLE 1.
Baseline Characteristics of Biologic-Treated Patients With Ulcerative Colitis Included in the Cohort by Disease Duration
| Baseline Characteristics | All Patients | <2 y | ≥2 y | P |
|---|---|---|---|---|
| No. patients | 160 | 43 | 117 | - |
| Patient characteristics | ||||
| Age at cohort entry, median (IQR), y | 36.0 (26.0–51.8) | 37.0 (23.0–51.0) | 40.2 (37.3–43.2) | 0.33 |
| Sex, males (%) | 50 | 49 | 50 | 0.89 |
| Disease duration, median (IQR), y | 4.5 (1.0–9.0) | N/A | N/A | - |
| Follow-up, median (IQR), mo | 24.0 (14.8–34.7) | 22.1 (14.4–24.7) | 28.6 (25.6–31.6) | <0.01 |
| BMI, median (IQR), kg/m2 | 24.3 (21.4–28.7) | 24.6 (21.5–28.7) | 25.8 (24.7–27.0) | 0.70 |
| Smoking status, No. (%) | ||||
| •Current smokers | 8 (5.0) | 0 (0.0) | 8 (6.8) | 0.03 |
| •Recent past smoker (<1 y from cohort entry) | 2 (1.3) | 1 (2.3) | 1 (0.9) | |
| •Former smokers | 39 (24.4) | 16 (37.2) | 23 (19.7) | |
| •Never smoker | 111 (69.4) | 26 (60.5) | 85 (72.7) | |
| Disease characteristics | ||||
| Disease extent, No. (%) | ||||
| •Extensive colitis | 98 (61.3) | 27 (62.8) | 71 (60.7) | 0.82 |
| •Left-sided colitis | 61 (38.1) | 16 (37.2) | 45 (38.5) | |
| •Proctitis | 1 (0.6) | 0 (0.0) | 1 (0.9) | |
| Disease severity, No. (%) | ||||
| •Mayo score 0 | 1 (1.0) | 0 (0.0) | 1 (1.4) | 0.93 |
| •Mayo score 1 | 10 (9.8) | 3 (10.3) | 7 (9.6) | |
| •Mayo score 2 | 27 (36.3) | 11 (37.9) | 26 (35.6) | |
| •Mayo score 3 | 54 (52.9) | 15 (51.7) | 39 (53.4) | |
| Prior IBD hospitalization <1 y from cohort entry (%) | 44 (27.5) | 14 (32.6) | 30 (25.6) | 0.39 |
| Treatment characteristics | ||||
| TNFα antagonists taken at cohort entry, No. (%) | ||||
| •Infliximab | 88 (55.0) | 27 (62.8) | 61 (52.1) | 0.74 |
| •Adalimumab | 31 (19.4) | 8 (18.6) | 23 (19.7) | |
| •Golimumab | 10 (6.3) | 2 (4.7) | 8 (6.8) | |
| •Certolizumab pegol | 1 (0.6) | 0 (0.0) | 1 (0.9) | |
| •Vedolizumab | 30 (18.8) | 6 (13.9) | 24 (20.5) | |
| No. prior TNFα antagonist failures | ||||
| •0 | 117 (73.1) | 34 (79.1) | 83 (70.9) | 0.64 |
| •1 | 34 (21.3) | 8 (18.6) | 26 (22.2) | |
| •2 | 8 (5.0) | 1 (2.3) | 7 (6.0) | |
| •3 | 1 (0.6) | 0 (0.0) | 1 (0.9) | |
| Prior steroid use <1 y from cohort entry, No. (%) | 130 (81.3) | 41 (95.4) | 89 (76.1) | <0.01 |
| Steroid use at cohort entry, No. (%) | 83 (51.9) | 27 (62.8) | 56 (47.9) | 0.09 |
| Prior use of immunomodulators, No. (%) | 85 (53.1) | 19 (44.2) | 66 (56.4) | 0.17 |
| Immunomodulator use at cohort entry, No. (%) | ||||
| •Azathioprine | 54 (60.7) | 16 (69.6) | 38 (57.6) | 0.34 |
| •6-mercaptopurine | 26 (29.2) | 4 (17.4) | 22 (33.3) | |
| •Methotrexate | 9 (10.1) | 3 (13.0) | 6 (9.1) | |
| CRP, median (IQR), mg/dL | 0.30 (0.10–1.40) | 0.50 (0.15–1.95) | 0.30 (0.10–1.30) | 0.18 |
| Albumin, median (IQR), g/dL | 4.10 (3.75–4.30) | 4.00 (3.70–4.30) | 4.10 (3.80–4.30) | 0.33 |
| Hgb, mean (SD), g/dL | 12.3 (2.1) | 11.8 (1.8) | 12.4 (2.2) | 0.14 |
| ESR, median (IQR), mm/h | 15.0 (6.3–28.0) | 18.0 (11.0–28.0) | 15.0 (6.0–28.0) | 0.58 |